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Centers for Disease Control and Prevention
Center for Preparedness and Response
COVID-19 in the United States: Insights from 
Healthcare Systems
Clinician Outreach and Communication Activity (COCA) Webinar
Friday, April 17, 2020
Continuing Education
Continuing Education is not offered for this COCA Call.
To Ask a Question 
▪ Using the Webinar System
– Click the Q&A button.
– Type your question in the Q&A box.
– Submit your question.
▪ If we are unable to get to your question during the call, you may also 
email your question to coca@cdc.gov. 
▪ For media questions, please contact CDC Media Relations at 404-639-
3286, or send an email to media@cdc.gov.
We want to hear from you!                                        
What best practices do you have to share? 
▪ Using the Webinar System
– Click the Q&A button.
– Type your question in the Q&A box.
– Submit your best practice.
▪ Or submit to coca@cdc.gov. 
▪ Facebook Live viewers, please leave your comment on Facebook or email 
coca@cdc.gov.
▪ Thank you!
For More Clinical Care Information on COVID-19
▪ Call COVID-19 Clinical Call Center at 770-488-7100 (24 hours/day).
▪ Refer patients to state and local health departments for COVID-19
testing and test results.
– Clinicians should NOT refer patients to CDC to find out where or 
how to get tested for COVID-19, OR to get COVID-19 test results.
▪ Visit CDC’s Coronavirus (COVID-19) website: 
https://www.cdc.gov/coronavirus
▪ Visit emergency.cdc.gov/coca over the next several days to learn about 
future COCA Calls.
Today’s Presenters
▪ Aaron Harris, MD, MPH (no slides)
Team Lead, Healthcare Systems Coordination Team
COVID-19 Response 
Centers for Disease Control and Prevention
▪ Nancy Foster (no slides)
Vice President, Quality & Patient Safety Policy
American Hospital Association
▪ David Reich, MD 
President, Chief Operating Officer
The Mount Sinai Hospital, NY 
▪ Amy Compton-Phillips, MD   
Executive Vice President, Chief Clinical Officer
Providence St. Joseph Health, WA
COVID-19 Response:
Challenges and Successes 
David L. Reich, MD
President and COO, The Mount Sinai Hospital
The views expressed in this presentation are 
those of the author and do not necessarily 
represent the opinion of the Centers for 
Disease Control and Prevention.
About The Mount Sinai Health System
▶8 hospitals located throughout 
NYC and Long Island 
▶> 4.1 million annual patient visits 
▶> 410 ambulatory practices
▶> 42,000 employees
▶Affiliated with the Icahn School 
of Medicine at Mount Sinai
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Case Identified in 
Westchester, NY
Mar. 5, 2020









In-house testing live, 
visitor restrictions, and 





> 1500 patients in 
MSHS
Jan. 29, 2020












>1000 patients in MSHS





Opening of Field 
Tent
Apr. 8.2020
Opened first COVID-19 
palliative care unit
Personal Protective Equipment
Shift to Droplet Precautions
▶NYC DOHMH updated their 
guidance to support droplet and 
contact precautions
▶Surgical Mask + Eye Protection
– N95-respirators reserved for 
aerosol-generating procedures
14NYC DOHMH Alert # 6 - COVID-19 Updates for New York City published 15Mar20
Contingency Standards for PPE 
▶Limited reuse and extended use of 
N95-respirators
▶Several units are “extended use PPE” 
units
– Extended use of isolation gowns
• The patient is not on contact precautions 
for another pathogen
• The gown is not ripped, torn or soiled
• Gloves are removed and hand hygiene is 
performed
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▶Daily briefings with senior level 
leadership
▶Twice daily huddles with local 
leadership
▶Crisis communication broadcast 
messages
▶Twice daily calls with bargaining units





▶ Redeployment of staff and leadership 
▶ Team-based care model
▶ Volunteers and external staff








Physical Plant and Increased Capacity
Critical Care and Negative Pressure Capacity (MSH)
▶ Transitioned 10 adult units to COVID-19 
ICUs
– 94 licensed beds to 240 adult ICU beds
– Doubled occupancy in ICUs by placing two 
patients in a single occupancy room
▶ Converted 260 patient rooms to negative 
pressure using HEPA exhaust fans
▶ Incorporated remote patient monitoring and 
point of care monitoring





Aerial view of Central Park Mount Sinai Morningside
Testing and Therapeutics
Rapid Expansion of Testing Capacity
▶Coordinated with public health laboratories for testing of both 
inpatients and symptomatic healthcare workers February 29
▶Initially partnered with a commercial laboratory to offer testing in our 
Emergency Departments and Ambulatory settings on March 10
▶Established limited in-house testing on March 14 and expanded to 
high-volume testing for MSHS on March 17
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COVID-19 Antibody Testing
▶ Adapted a research laboratory-based serum antibody assay to the CLIA-
certified clinical microbiology laboratory
▶ Began screening high-risk healthcare workers and MSHS COVID-19 PCR 
positive patients on March 24, 2020
▶Offered plasma donation to individuals with antibody titers > 1:320
▶ Adjusted timing to better define optimal eligibility for donation
– Over 21 days since symptom onset and full resolution of symptoms for over 14 
days
– Prioritized known positive COVID-19 recovered patients interested in plasma 
donation in partnership with New York Blood Center 







• Hospitalized with fever
• SpO2 > 93%
• Radiographic evidence of 
pulmonary infiltrates
• Hospitalized with fever
• SpO2 ≤ 93%
• Radiographic evidence of 
pulmonary infiltrates























If CRP >150 or D-Dimer >2.5




















Moderate disease Critical disease











• Symptom-free for 
14 days









- >18 years old
- Lab-confirmed





• Mount Sinai 
Hospital
• eIND and EAP 
protocols with the 
FDA
• Blood type 
matching
• Phone consent 
with patients
• Expansion to 














• Continued clinical 
monitoring









automation  and 
modeling
MSHS Convalescent Plasma Program
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Convalescent Plasma Program
▶Started March 24, 2020 under FDA eIND (3/24 – 4/11/20)







Week 1 3/24 – 3/30/20 3 N/A 3
Week 2 3/31 – 4/6/20 16 N/A 16
Week 3 4/7 – 4/13/20 20 20 40
Total 39 20 59
Amanat F et al. A serological assay to detect SARS-CoV2 seroconversion in humans. Published March 16, 2020 https://doi.org/10.1101/2020.03.17.20037713.
https://www.uscovidplasma.org
Increasing Ventilator Capacity and Innovation





▶Centralized assembly, testing, and distribution of 
devices for the health system
– Utilized medical students and simulation laboratory
▶ Leveraged simulation lab to facilitate several 
ventilator innovations 
– Upgrade of home ventilators to critical care capable 
ventilators 













Ventilators Anesthesia Transport/Specialty BiPAP HFNC




















• Inclusion: All admitted patients with COVID-19
• Exclusion: High risk of bleeding as judged by 
treating physician
• Obtain: Baseline CBC, PT/PTT, D-dimer and daily 
CBC, D-dimer
• Anticoagulant: Rivaroxaban may be used in place of 
Apixaban if CrCl >50.
• Consider treatment-dose AC (Apixaban 5mg PO 
BID)† for 2 weeks post-discharge for patients on 
therapeutic anticoagulation while hospitalized
• High-risk for bleeding, consider:
- Platelet count <50,000 
- INR >1.5
- Current or recent bleeding










Apixaban 5mg PO BID†
or IV heparin (standard 












Admitted patients with COVID-19 
Admitted to ICU?
IV heparin (standard VTE 
treatment PTT target) or
Enoxaparin SC 1mg/kg Q12 hr.
Consider for tPA study.
Apixaban  2.5-5mg PO BID† or 





# High Risk: No precise metrics exist. Consider exam (eg, O2 sat<90%, 
RR >24), ↑O2 requirement (eg, ≥4L NC), labs (eg, ↑d-dimers, C-reactive 
protein)
^ Efficacy and dose not established; prophylactic or treatment dose 
acceptable
† If 2 of 3 reduce apixaban to 2.5 mg BID: ≥80 years, wt ≤60 kg, 
creatinine >1.5. 







Faster, Better Together: Health System 
Lessons Learned in Tackling COVID-19
Amy Compton-Phillips, MD
Executive Vice President and Chief Clinical Officer
36
▪ The views expressed in this presentation are those of the author and 





Providence COVID Response Journey
CRISIS PLANNING
• Learning from others
• Communications
PATIENT #1
• January 20, 2020 – Providence Everett
EMERGENCY COMMAND CENTER: 
• Established communications rhythms
PANDEMIC PLAYBOOK
• Protocols for People, Places, Products for 
Triage Levels 1-3
TECH-ENABLED SEAMLESS EXPERIENCE
• Ideal patient journey
MOBILIZE COMMUNITY 
RESOURCES
• Resource Staffing Tool
• Local and regional 
partnerships
FUTURE OF CLINICAL 
CARE DELIVERY
• Keeping patients safe in the 
age of COVID




Planning is the antidote to Panic
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▪ Create simplicity out of complexity
▪ Leverage 21st century technology
▪ Clarify ways to manage patient and caregiver safety











(Hospitals, Beds, OR, 
Med/Surg, ASCs, etc.)
Triggers to Next 
Level
(When capacity exceeds the 
threshold on any of the 
following components, we must 




Internal Stretch Capacity/Anticipating Additional Surge 
Demand
Triage Level 3
Community/Government Support & 
Region-Wide Capabilities
Phase A Phase B
• Current staff
• Tele-health
• Planning for surge staff
• Begin training of staff to take on 
atypical tasks
• Coordinate with coms team.
• Labor pool expansion; connect 
with contracted provider groups 
and credentialing
• Ethics support (planning)
Phase A Phase B
• Usual care 
sites
• Begin cohorting strategies
• Command center planning
• IT planning for alternative. 
Sites
Phase A Phase B
• Care per usual 
guidelines
• Conservation protocols
Normal Internal Capacity at or Above:
• 95% utilization of critical care 
personnel (intensivists, critical care RNs)
• 95% Med/Surg beds and/or ICU capacity
Phase A Phase B
• Mobilize Surge staff*
• Initiate team-based care staffing model
• Mobilize Tele-ICU / home monitoring -
• Redeploy Ambulatory & ASC staff to IP*
• Mobilize Palliative Care, Spiritual Care
• Initiate disaster 
credentials plan**
• Triage process 
activation: care team 
considerations
• Ethics support 
(contingency)
Phase A Phase B
• Stop all elective non-emergent procedures
• Implement Patient cohorting plans
• Mobilize alternate sites for care e.g. PACU, OR, ASC 
OR, Med/Surg
• Coordinate with 
community, regional, 
state and federal govt. 
partners to support 
public health crisis
Phase A Phase B
• Forced conservation governance
• Implement Ventilator support algorithm
• Immediate adoption of revised PPE substitution and 
minimum standards
• Initiate Clinical Ethics 
Surge plan
• Substitution alternative 
for critical shortages
Internal Stretch Capacity at or Above:
• Forecasting tools suggest upcoming surge
• 95% utilization of critical care personnel (Intensivists, Hospitalists, CCRNs, RTs 
Anesthesia, CRNAs) or
• 95% ICU utilization, or
• 90% ventilator capacity, or
• Critical supply or PPE < 4-5 days on hand
Internal Stretch Capacity at or Above:
• N/A
• Define staffing needs and levels of care at alternate 
sites
• Ethics support (crisis)
• Coordinate with community, regional, state and federal 
government partners to support public health crisis
• Consider transfers to other community IP facilities or 
outside if capacity available
• Define need for alternate site needs: ICU, medical, 
convalescent care, etc.
• Coordinate with community, regional, state and federal 
government partners to support public health crisis
• Procure supplies, equipment, PPE for alternate care 
locations
Level 2 and 3 Planning 
should start in Level 1
Conventional Contingency Crisis
…
*This content is covered in Triage Level 1, ‘Planning for Surge Staff’
**Not included in this version of the playbook or included in alternate Triage level (content remains the same).
Clinical Disaster Planning Framework
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COVID Planning Pandemic Planning Manage COVID Crisis Post Crisis
Day-1 Day-100ish
Clinical Care in a COVID-19 World
❑ What are the capacity triggers 




▪ Patient Flow and 
Clinical Care Recovery Process
❑ Testing Protocols
❑ Staff and Patient Health from 
COVID-19
❑ Continue treatment for 
COVID-19 cases
❑ Reverse cohorting
❑ Continuing the use of 
Telehealth for patient care
❑ Routine Preventative and 
Interventional treatment 
options
❑ How do we avoid Caregiver 
and Staff burn-out while 
scaling non-COVID patients?







Turn data into information into 
insight into action
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Providence Clinical Analytics: CoVERED Tool
▪Practical information accessible across our organization for decision making.
46
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% of patients living in a ZIP who present with fever + cough + shortness of breath and are flu-negative
CoVERED Tool EMR-based syndromic surveillance: Key Markets
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Acute Chronic Population Health
• During COVID-19 outbreak, hospitals experienced a 
reduction in standard acute care patients. 
• Hospitals must develop and implement plans to address 
patients’ concerns of infection to encourage patients to 
return.
• Chronic conditions of patients may worsen during 
infection waves, which may result in increased need of 
care once waves subside.
• Potential for increase in elective surgeries due to 
mandatory deferments during infection waves.
• Anticipated increase of new patients resulting from the 
unintended consequences of the pandemic, like:
• Increased behavior-induced consequences, such as 
drug problems and alcoholism; and
• Deterioration of mental health, such as increased 



















As an effect of the COVID-19 pandemic, many patients deferred care. In the upcoming months, we expect 
the return of these patients, as well as anticipate new patient groups, to need care:
Deferred Care Community Needs
Care & 
Planning 











Future of Clinical Care
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Biggest Learnings
▪ Hope for the best, but plan for worst: Expect more epidemics
▪ Learn from the past: But transition to what could be
▪ Advocate together: Act on collective intelligence for the benefit of all
▪ Change the future of medicine: Reimagine the role 21st century tech tools
▪ The environment is chaotic: Rely on science, not fear
▪ Establish a consistent voice: Listen to all, then align, communicate and repeat.
Providence is sharing its process and tools—please reach out at 
COVIDresponse@providence.org to be connected to our services division
To Ask a Question  
▪ Using the Webinar System
– Click on the Q&A button in the Zoom webinar system.
– Type your question in the Q&A box.
– Submit your question.
– You may also email your question to coca@cdc.gov.
▪ For media questions, please contact CDC Media Relations at 404-639-3286 or email media@cdc.gov.
▪ For more Clinical Care information on COVID-19
– Call COVID-19 Clinical Call Center at 770-488-7100 (24 hours/day).
– Refer patients to state and local health departments for COVID-19 COVID19 testing and test 
results.
• Clinicians should NOT refer patients to CDC to find out where or how to get tested for 
COVID-19 OR to get COVID-19 test results.
– Visit CDC’s Coronavirus (COVID-19) website: https://www.cdc.gov/coronavirus.
Today’s COCA Call Will Be Available On-Demand
When:  A few hours after the live call
What:  Video recording
Where:  On the COCA Call webpage at
https://emergency.cdc.gov/coca/calls/2020/callinfo_041720.asp
On COCA’s Facebook Page immediately after the live call at
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity/
COCA Products & Services
COCA Call Announcements contain all information 
subscribers need to participate in COCA Calls. COCA 
Calls are held as needed.
Monthly newsletter that provides information on CDC 
training opportunities, conference and training 
resources, the COCA Partner Spotlight, and the 
Clinician Corner.
As-needed messages that provide specific, immediate 
action clinicians should take. Contains comprehensive 
CDC guidance so clinicians can easily follow 
recommended actions.
COCA Products & Services 
Informs clinicians of new CDC resources and guidance 
related to emergency preparedness and response. 
This email is sent as soon as possible after CDC 
publishes new content.
CDC's primary method of sharing information about 
urgent public health incidents with public information 
officers; federal, state, territorial, and local public 
health practitioners; clinicians; and public health 
laboratories.
Monthly newsletter providing updates on emergency 
preparedness and response topics, emerging public 
health threat literature, resources for health 
professionals, and additional information important 
during public health emergencies and disasters.
Join COCA’s Mailing List
▪ Receive information about:
– Upcoming COCA Calls
– Health Alert Network (HAN) messages
– CDC emergency response activations
– Emerging public health threats
– Emergency preparedness and 
response conferences and training 
opportunities
emergency.cdc.gov/coca 
Join Us on Facebook
Thank you for joining us today! 
emergency.cdc.gov/coca 
